GISAR German Interdisciplinary Sarcoma Registry
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
About this trial
GISAR has an open and modular setup. It is sought to include as many German sarcoma and CS patients (i.e. sarcoma and CS patients treated in Germany) in the registry as possible. A basic data set should be collected on every included patient). In order to adress specific scientific questions, additionally detailed data can be collected in defined patient groups (e.g. effectiveness / adverse effects of systemic therapies in defined situations) within the context of sub-project add-on modules. This data collection can be prospective or retrospective depending on the sub-project
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Histological verified bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity like giant cell tumors of the bone (GCTB), desmoid tumors, atypical lipomatous tumors etc. - independent of therapy form and therapy line - or Histological verified sarcomatoid carcinomas/ carcinosarcomas: tumors with histological, cytological, or molecular properties of both epithelial tumors ("carcinoma") and mesenchymal tumors ("sarcoma") - independent of therapy form and therapy line.
Signed informed consent form or equivalent (s. chapter 10)
Age ≥18 years
Disqualifiers
none
Trial population
Adults ≥18 years, verified for bone or soft tissue sarcomas including bone and soft tissue tumors with borderline histological results or with unclear histological dignity (like giant cell tumors of the bone \[GCTB\], desmoid tumors, atypical lipomatous tumors) as well as carcinosarcomas - independent of kind of therapy and therapy line. Thus, the registry is open for all subtypes of sarcomas and CS.
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
9,000 Participants
are grouped into 1 trial groupGroup A: Patients with bone or soft tissue sarcomas or carcinosarcomas
Trial outcomes
Primary outcomes
1
Incidence of sarcoma preferably specific to the different subtypes
Generation of epidemiological data
Time frame
1 year2
Prevalence of sarcoma preferably specific to the different subtypes
Generation of epidemiological data
Time frame
1 year3
Prognosis of sarcoma preferably specific to the different subtypes
Generation of epidemiological data
Time frame
1 yearSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov